Asimov, a synthetic biology company focused on therapeutic design and manufacturing, has entered into a licensing agreement with RevOpsis Therapeutics. RevOpsis specializes in developing next-generation multispecific biologics for ophthalmic therapies. This partnership stems from a successful cell line development campaign using Asimov’s CHO Edge System for RevOpsis’s lead asset, RO-104.
The agreement grants RevOpsis the right to utilize the CHO Edge System for the development and commercialization of RO-104. This innovative, first-in-class fully modular tri-specific biologic targets retinal vascular diseases. RO-104 is engineered to simultaneously address the three primary angiogenic pathways (VEGF-A, VEGF-C, and Ang-2) involved in the progression of these diseases, including neovascular age-related macular degeneration (AMD) and diabetic macular edema. RevOpsis anticipates initiating IND-enabling studies for RO-104 in January 2025.
Asimov’s CHO Edge System offers a comprehensive solution for bioproduction. It includes a GMP-banked CHO-K1 glutamine synthetase (GS) knockout host cell line, with a GS-Fut8 double knockout option for afucosylated antibody production. Furthermore, the system provides a hyperactive transposase, a vast library of over a thousand characterized genetic parts for vector design, and sophisticated AI and biophysics models. This combination enables reliable generation of stable cell lines exhibiting high titer and superior product quality. The system also facilitates the optimization of expression vectors and bioreactor processes for various biologic modalities.
This licensing agreement signifies the growing adoption of Asimov’s CHO Edge System. The platform will serve as a foundational element in RevOpsis’s bioproduction process for RO-104, a therapy aimed at addressing significant unmet needs within a growing patient population. Asimov is committed to supporting RevOpsis’s biologic development throughout clinical trials. RevOpsis, dedicated to the rapid discovery and development of novel multispecific therapies, leverages its modular RevMod™ Platform comprised of fully human libraries. The integration of Asimov’s CHO Edge System is expected to significantly enhance the development and commercialization of RO-104 for the treatment of retinal vascular diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
